InVivo Therapeutics (NVIV) Announces Appointment Of Jeffrey Hatfield To Board Of Directors
11/2/2016 10:41:18 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Jeffrey Hatfield to its Board of Directors. Mr. Hatfield most recently served as President, Chief Executive Officer, and Board Member for Vitae Pharmaceuticals and served in those capacities since joining the company in March 2004. Mr. Hatfield funded the company privately from 2005 to 2014 via three separate partnering transactions and took Vitae Pharmaceuticals public in 2014. On September 14, 2016, Allergan Plc announced that it had entered into a definitive agreement to purchase Vitae Pharmaceuticals for approximately $639 million in cash.
comments powered by